Medtronic Launches Covidien Surgical Device to Treat Peripheral Artery Disease
Monday, April 13, 2015
Source: Fierce Medical Devices
Medtronic ($MDT) announced the U.S. launch of its HawkOne directional atherectomy system, for surgical treatment of peripheral artery disease, or blocked and calcified arteries in the arms or legs. The device was obtained via Medtronic's $50 billion acquisition of Covidien.
Medtronic says that the HawkOne can treat calcified lesions more than twice as effectively as its prior generation TurboHawk directional atherectomy device. The company pointed to a study published in the Journal of the American College of Cardiology, Cardiovascular Interventions, which showed directional atherectomy had a 95% limb salvage in patients with critical limb ischemia and 78% effectiveness in keeping treated arteries open in patients at 12 months.
Directional atherectomy devices enter the body via catheter and use a directional cutter that can be positioned within the diseased vessel for optimal performance and increase in blood flow.